FDA Answers sNDA For Spectrum's Fusilev With "Complete Response"
This article was originally published in The Pink Sheet Daily
If two therapies perform similarly in a head-to-head trial, can a sponsor use the failed superiority data to claim non-inferiority? Spectrum hopes so.
You may also be interested in...
Buyer Spectrum downplays supplemental BLA delay in front-line non-Hodgkins lymphoma.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.